AngioDynamics, Inc. (ANGO) Wednesday reported net loss of $4.41 million or $0.11 per share for the third quarter, significantly lower than $187.74 million or $4.67 per share loss in the same quarter a year ago, primarily due to goodwill impairment charges of $159.48 million in the prior-year quarter.
Third-quarter results beat analysts' view. The medical technology company also raised its full-year outlook above the Street expectations. Its shares were more than 10 percent up in pre-market.
Excluding one-time items, loss narrowed to $3.1 million or $0.08 per share, from $6.5 million or $0.16 loss per share a year ago.
Sales for the quarter declined to $72 million from $75.18 million last year. Proforma sales grew 9.2 percent to $72.01 million from $65.97 million.
On average, 3 analysts expected the company to report loss of $0.13 per share on sales of $70.3 million for the quarter. Analysts' estimates typically exclude special items.
For fiscal 2025, the company now expects sales to be in the range of $285 - $288 million, up from $282 - $288 million guided earlier.
Adjusted loss per share is expected between $0.31 and $0.34, an improvement from prior guidance of a loss of $0.34 to $0.38.
The consensus estimate for loss per share stands at $0.37 on sales of $284.91 million.
AngioDynamics stock had closed at $9.66, up 2.88 percent on Tuesday. It has traded in the range of $5.47 - $13.50 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
December 12, 2025 15:14 ET Central bank decisions dominated the economic news flow this week led by the Federal Reserve. Trade data from the U.S. also gained attention. The Canadian and Swiss central banks also announced their interest rate decisions. Inflation data from China was in focus as the country released the latest consumer price and producer price data.